CANVIREX

CanVirex is a spin-off from the Heidelberg University Hospital, founded in 2017 in Basel, Switzerland. The company develops novel immunotherapeutics for the treatment of cancer and is ready for the clinical translation of its proprietary cutting-edge platform technology with the potential to become a game changer in immuno-oncology... CanVirex AG operates out of its headquarter in Basel, Switzerland. Research and clinical activities related to CanVirex's pipeline are performed at the Heidelberg University Hospital, Germany... CanVirex's measles vector-based platform represents a highly promising technology for cancer immunotherapy and vaccine development against infectious diseases. Our technology allows us to genetically modify measles viruses with a so called transgene - a therapeutic snippet of genetic code - that is inserted into the virus genome. When these modified viruses are administered to a patient, they selectively infect and reproduce in target cells. Depending on the..

Also known as: CanVirex AG

Primary location: Basel Belgium